World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
76
Citations
24573
World Ranking
1880
National Ranking
16

Finn Sellebjerg publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Finn Sellebjerg sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 424 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Finn Sellebjerg D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Finn Sellebjerg sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 76 D-Index — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Finn Sellebjerg is affiliated with Copenhagen University Hospital in Denmark and has contributed extensively to the field of medicine, with a particular focus on multiple sclerosis and related neurological disorders. Their research spans pathology, neurology, immunology, oncology, and rheumatology.

The scientist's recent papers cover significant topics in multiple sclerosis, including disease progression, treatment strategies, and biomarkers. Notable publications include:

  • Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis, 2021, JAMA Neurology
  • Locus for severity implicates CNS resilience in progression of multiple sclerosis, 2023, Nature
  • Initial high-efficacy disease-modifying therapy in multiple sclerosis, 2020, Neurology
  • Serum neurofilament light as a biomarker in progressive multiple sclerosis, 2020, Neurology
  • The gut microbiota in multiple sclerosis varies with disease activity, 2023, Genome Medicine

Frequent co-authors collaborating with Sellebjerg include:

  • Melinda Magyari
  • Jeppe Romme Christensen
  • Helle Bach Søndergaard
  • Xavier Montalbán
  • Per Soelberg Sørensen

Sellebjerg's work has been published primarily in journals such as:

  • Multiple Sclerosis and Related Disorders
  • Neurology
  • Multiple Sclerosis Journal
  • Frontiers in Immunology
  • Neurology Neuroimmunology & Neuroinflammation

Their research fields emphasize medicine with a strong focus on subfields including pathology and forensic medicine, neurology, immunology, oncology, and rheumatology. This multidisciplinary approach supports investigations into complex neurological and immune-related diseases.

Main research topics covered in Sellebjerg's body of work are:

  • Multiple Sclerosis Research Studies
  • Peripheral Neuropathies and Disorders
  • Immunotherapy and Immune Responses
  • Polyomavirus and related diseases
  • T-cell and B-cell Immunology
  • Systemic Lupus Erythematosus Research
  • Rheumatoid Arthritis Research and Therapies

Best Publications

  • Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

    Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer

  • Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility

    Unknown

  • Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

    Ashley H. Beecham;Nikolaos A. Patsopoulos;Nikolaos A. Patsopoulos;Dionysia K. Xifara;Mary F. Davis

  • Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients

    Torben L. Sørensen;Marie Tani;Jakob Jensen;Virginia Pierce

  • Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course

    Mohsen Khademi;Ingrid Kockum;Magnus L Andersson;Ellen Iacobaeus

  • Multiple sclerosis: A study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system

    Torben L. Sørensen;Corinna Trebst;Pia Kivisäkk;Karen L. Klaege

  • CCR1+/CCR5+ Mononuclear Phagocytes Accumulate in the Central Nervous System of Patients with Multiple Sclerosis

    Corinna Trebst;Torben Lykke Sørensen;Pia Kivisäkk;Martha K. Cathcart

  • Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression

    Jeppe Romme Christensen;Lars Börnsen;Rikke Ratzer;Fredrik Piehl

  • Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS

    F. Sellebjerg;L. Börnsen;M. Khademi;M. Krakauer

  • T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis.

    Chris J Hedegaard;Martin Krakauer;Klaus Bendtzen;Henrik Lund

  • CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis

    Finn Sellebjerg;Hans O Madsen;Claus V Jensen;Jakob Jensen

  • FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS

    Yawei Liu;Robert Carlsson;Manuel Comabella;Jun Yang Wang

  • Differential microRNA expression in blood in multiple sclerosis

    Helle Bach Søndergaard;Dan Hesse;Martin Krakauer;Per Soelberg Sørensen

  • Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls

    Sergio E. Baranzini;Pouya Khankhanian;Nikolaos A. Patsopoulos;Michael Li

  • A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis

    H G Roed;A Langkilde;F Sellebjerg;M Lauritzen

  • Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

    Per Soelberg Sorensen;Nils Koch-Henriksen;Nils Koch-Henriksen;Thor Petersen;Mads Ravnborg

  • Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis

    T. L. Sørensen;F. Sellebjerg;C. V. Jensen;R. M. Strieter

  • Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system

    F. Sellebjerg;T.L. Sørensen

  • Natalizumab in progressive MS Results of an open-label, phase 2A, proof-of-concept trial

    Jeppe Romme Christensen;Rikke Ratzer;Lars Börnsen;Mark Lyksborg

  • Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis.

    Marina R von Essen;Cecilie Ammitzbøll;Rikke H Hansen;Eva R S Petersen

  • The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers

    M. Khademi;L. Bornsen;F. Rafatnia;M. Andersson

  • Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity

    D. Hesse;F. Sellebjerg;P. Soelberg Sorensen

  • IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.

    P. Soelberg Sorensen;J. Haas;F. Sellebjerg;T. Olsson

Frequent Co-Authors

Per Soelberg Sørensen
Per Soelberg Sørensen University of Copenhagen
Hanne F. Harbo
Hanne F. Harbo Oslo University Hospital
Ingrid Kockum
Ingrid Kockum Karolinska Institute
Jan Hillert
Jan Hillert Karolinska Institute
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Michael Christiansen
Michael Christiansen Statens Serum Institut
Manuel Comabella
Manuel Comabella Vall d'Hebron Institut de Recerca
Tomas Olsson
Tomas Olsson Karolinska Institute
Kjell-Morten Myhr
Kjell-Morten Myhr University of Bergen
Fredrik Piehl
Fredrik Piehl Karolinska Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare fields can open diverse career opportunities. Nursing degrees, for example, provide a strong foundation in patient care and biological sciences, closely linked to immunological principles. Students looking to enter nursing quickly might consider accelerated nursing programs, which offer a faster route to obtaining a Bachelor of Science in Nursing (BSN).

Entry into nursing is also accessible through LPN pathways. Those seeking easier admission can explore easy admission LPN programs, which provide essential skills for patient care and serve as stepping stones to advanced nursing roles.

Advanced practice nurses, such as Nurse Practitioners (NPs), often work closely with immunologists in clinical environments. Prospective students might find guidance by looking into what is the easiest NP program to identify programs suited to their needs and timelines.

Specializations like Psychiatric Mental Health Nurse Practitioner (PMHNP) combine mental health with immunological considerations. For those interested, selecting programs with strong clinical support is crucial; the best PMHNP programs offer excellent clinical placement rates to enhance hands-on learning.

Best Scientists Citing Finn Sellebjerg

Trending Scientists

Recently Published Articles